Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection
IND-enabling studies underway, with Phase I study initiation expected in 2Q26
Webcast and conference call to be held today at 4:30 pm ET
NEWARK, CALIFORNIA / ACCESS Newswire Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. The triple agonist PN-477 is designed to offer the optimal combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration.
'We are very pleased to nominate development candidate PN-477, a promising potential best-in class oral GLP-1, GIP, GCG receptor tri-agonist peptide which has demonstrated optimal absolute and relative activity against all three hormone receptors in preclinical testing,' said Dinesh V. Patel, PhD, President and CEO of Protagonist. 'PN-477 is specifically engineered to be orally stable with attention to the relative balance of potencies against the three receptors to potentially leverage their beneficial effects on weight loss and optimal body composition while mitigating their adverse effects. As with our previous drug candidates and late-stage assets, PN-477 is a testament to the power of our peptide technology platform, including the ability to deliver first- and best-in-class targeted oral and injectable peptide therapeutics.'
PN-477 has completed extensive preclinical evaluation including oral and metabolic stability, potency, pharmacokinetics and pharmacodynamics studies, and has demonstrated effects in preclinical models of obesity and glycemic control. PN-477 has shown potent in vitro activity in activating the GLP-1, GIP, and GCG receptors. PN-477 also demonstrated robust preclinical proof-of-concept in various animal studies including the diet induced obesity (DIO) preclinical mouse model, normal dogs, and cynomolgus monkeys. Overall, PN-477 has the right balance of potency, oral and in-vivo stability, and pharmacokinetic properties to enable parallel development both as a once-daily oral (PN-477o) and once-weekly injectable (PN-477sc) treatment options. IND enabling studies of PN-477 are underway and initiation of Phase 1 clinical studies is anticipated in the second quarter of 2026.
'While GLP-1 agonists have dominated the market thus far, there remains a broad opportunity for novel therapeutics with better body weight loss, higher ratio of fat to lean mass loss, tolerability and additional beneficial effects in obesity-related comorbidities. A triple GLP-1, GIP, GCG receptor agonist peptide that offers weight loss on par with the best injectable treatments options, as well as the optionality provided by both oral and injectable routes of administration, would be an important therapeutic breakthrough and represents another potential blockbuster drug opportunity for Protagonist,' added Dr. Patel. 'We look forward to moving PN-477 into first-in human clinical Phase 1 studies in the second quarter of 2026.'
Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on Monday, June 30 th at 4:30 pm ET are:
US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13754335
The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and oral hepcidin.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of PN-477, and the timing of PN-477 clinical development. In some cases, you can identify these statements by forward-looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext. 1
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
19 minutes ago
- Business Upturn
IROBOT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in IRobot (IRBT) of the Class Action Lawsuit and Encourages Investors to Inquire About Their Rights
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses IRobot (IRBT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in any of the above companies between January 29, 2024 and March 11, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against iRobot Corporation ('iRobot' or the 'Company') (NASDAQ:IRBT) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired iRobot securities between January 29, 2024 and March 11, 2025, both dates inclusive (the 'Class Period'). Investors have until September 5, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) iRobot overstated the extent to which the Restructuring Plan would help the Company maintain stability after the termination of the Amazon Acquisition; (ii) as a result, it was unlikely that iRobot would be able to profitably operate as a standalone company; (iii) accordingly, there was substantial doubt about the Company's ability to continue as a going concern; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times. On March 12, 2025, iRobot issued a press release reporting its fourth quarter and full year 2024 financial results. For the quarter, iRobot reported a loss of $2.06 per share on revenue of $172 million, representing a 44% year-over-year decline. iRobot also cautioned investors that 'there can be no assurance that [iRobot's] new product launches will be successful due to potential factors, including, but not limited to consumer demand, competition, macroeconomic conditions, and tariff policies.' Accordingly, 'given these uncertainties and the implication they may have on the Company's financials, there is substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of its consolidated 2024 financial statements.' In addition, the press release stated that, in light of the foregoing developments, iRobot was cancelling its fourth-quarter and full-year 2024 results conference call and webcast, and that the Company would not be providing a 2025 outlook. Market analysts were quick to comment on iRobot's announcement. For example, on March 12, 2025, an analyst from Seeking Alpha downgraded iRobot to a sell rating from a hold rating 'due to [a] bleak outlook,' stating that 'iRobot's business prospects have deteriorated significantly since the Amazon acquisition fell through, leading to massive layoffs and growing losses,' 'Q4 earnings were disastrous, missing guidance and showing worsening gross margins due to excess inventory and lower sales volumes,' 'iRobot's future is uncertain, with substantial doubts about its viability within the next 12 months, despite ongoing discussions with its primary lender,' and that the Company's 'survival hinges on new Roombas being a hit, which seems unlikely.' That same day, in an article entitled 'Why iRobot Stock Is Crashing Today,' The Motley Fool stated, in relevant part, that 'iRobot's costly restructuring efforts — including a 50% workforce reduction — have yet to yield stability.' On this news, iRobot's stock price fell $3.255 per share, or 51.58%, over the following two trading sessions, to close at $3.055 per share on March 13, 2025. If you purchased or otherwise acquired iRobot shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Time Business News
8 hours ago
- Time Business News
The Role of AI in Personalizing the Customer Journey
Personalization is no longer just a buzzword—it's a critical component of a successful customer experience strategy. As competition intensifies and consumer expectations rise, businesses must deliver hyper-personalized experiences to stand out. This is where Artificial Intelligence (AI) plays a transformative role. AI is revolutionizing how brands understand, interact with, and serve their customers throughout the buyer journey. From awareness to post-purchase, AI enables businesses to tailor interactions at scale, in real-time. Modern consumers expect brands to know who they are, what they want, and when they want it. According to McKinsey & Company, companies that excel at personalization generate 40% more revenue from those activities than average players. Additionally, 71% of consumers expect companies to deliver personalized interactions, and 76% get frustrated when this doesn't happen. In other words, personalization isn't a luxury—it's an expectation. AI-powered personalization refers to using machine learning, natural language processing (NLP), and predictive analytics to tailor customer experiences across various channels and touchpoints. It leverages real-time and historical data to make, like courier package delivery systems, intelligent decisions about what content, product, or message to serve each user. Unlike traditional rule-based personalization, AI systems learn and adapt continuously. They identify patterns and make recommendations with increasing accuracy over time. In the initial stage of the customer journey, AI helps brands deliver the right message to the right audience. AI in programmatic advertising allows for real-time bidding and targeting based on behavioral data. AI-powered tools like Meta's Advantage+ and Google Ads' Smart Bidding automatically optimize ad performance. Predictive algorithms analyze customer segments and choose the best creative formats or messaging. Once a prospect shows interest, AI refines the experience further by delivering personalized content or product recommendations. E-commerce platforms like Amazon and Shopify use AI to suggest products based on browsing history, cart activity, and similar customer behavior. Content recommendation engines (like those used by Netflix or YouTube) keep users engaged longer by suggesting personalized media options. When customers are ready to convert, AI simplifies the process: AI chatbots provide real-time answers to pre-purchase questions, increasing conversion rates and reducing support costs. Dynamic pricing algorithms adjust prices based on demand, user behavior, and competitor pricing. Email automation platforms like Klaviyo and Mailchimp use AI to send personalized messages at optimal times. After a purchase, AI plays a critical role in retention: Predictive analytics helps identify at-risk customers and trigger proactive retention campaigns. AI suggests loyalty rewards based on customer value and behavior. Post-purchase emails, tailored with AI, recommend complementary products or services. Customer Data Platforms (CDPs): Aggregate and unify customer data from various sources Aggregate and unify customer data from various sources AI-driven CRM Systems: Salesforce Einstein, HubSpot AI, and Zoho Zia use AI integration to guide sales and marketing decisions. Salesforce Einstein, HubSpot AI, and Zoho Zia use AI integration to guide sales and marketing decisions. Recommendation Engines: Tools like Dynamic Yield, Adobe Target, and Algolia personalize content and product suggestions Tools like Dynamic Yield, Adobe Target, and Algolia personalize content and product suggestions Natural Language Processing: Powers chatbots like Drift, Intercom, and ChatGPT-based solutions to offer human-like support. While powerful, AI-driven personalization comes with challenges: Data privacy concerns: Striking a balance between personalization and respecting privacy is crucial. Transparency and compliance with GDPR and CCPA are non-negotiable. Striking a balance between personalization and respecting privacy is crucial. Transparency and compliance with GDPR and CCPA are non-negotiable. Bias in algorithms: Poorly trained models may reinforce biases, leading to inaccurate personalization. Poorly trained models may reinforce biases, leading to inaccurate personalization. Integration complexity: AI systems require clean, structured data and often need integration with legacy systems. Amazon: Amazon uses AI extensively to personalize product recommendations, which account for 35% of total sales. Their recommendation system is based on collaborative filtering, deep learning, and clickstream analysis. Spotify: Spotify's AI tailors playlists like Discover Weekly and Release Radar to individual listening habits. This personalization drives user loyalty and increases listening time. Starbucks: Through its Deep Brew AI engine, Starbucks customizes offers, drink suggestions, and email content based on customer behavior and weather, location, and order history. The next wave of AI will be conversational and contextual. As technologies like Generative AI, augmented reality (AR), and edge AI advance, personalization will go beyond product suggestions and into immersive, human-like experiences. We're also likely to see more AI Employees—virtual brand representatives that engage with customers across platforms like social media, email, and websites in real-time, offering personalized assistance at scale. The role of AI in personalizing the customer journey is undeniable. It empowers brands to deliver value-driven, relevant, and seamless experiences at every stage of the funnel. As customer expectations evolve, the businesses that win will be those that invest in intelligent, AI-powered personalization systems. Personalization at scale is no longer a future goal—it's a present necessity. TIME BUSINESS NEWS
Yahoo
12 hours ago
- Yahoo
REGISTRATION OF THE COMBINATION OF SHARES OF DIGITALIST GROUP PLC, AND ADJUSTMENT OF THE MAXIMUM NUMBERS OF SHARES AVAILABLE FOR SUBSCRIPTION UNDER THE COMPANY'S CONVERTIBLE LOANS AND 2021 STOCK OPTION PROGRAM, AND THE SUBSCRIPTION PRICES
REGISTRATION OF THE COMBINATION OF SHARES OF DIGITALIST GROUP PLC, AND ADJUSTMENT OF THE MAXIMUM NUMBERS OF SHARES IN THE COMPANY AVAILABLE FOR SUBSCRIPTION UNDER THE COMPANY'S CONVERTIBLE LOAN INSTRUMENTS AND THE 2021 STOCK OPTION PROGRAM, AS WELL AS THE SUBSCRIPTION PRICES Digitalist Group Plc Stock Exchange Release 16 August 2025 at 11:05 Combination of Shares and Related Directed Share Issue Without Consideration, Redemption and Cancellation of Shares Digitalist Group Plc ('Digitalist Group' or the 'Company') has, on the previously announced combination date of 15 August 2025, implemented the combination of the Company's shares, i.e. the reduction of the number of shares, as well as the related directed share issue without consideration, redemption of shares and cancellation of shares. Following the combination of shares, the Company's new total number of shares is 2,773,721. The new number of shares has today, 16 August 2025, been registered with the Trade Register maintained by the Finnish Patent and Registration Office, and trading in the Company's shares with the new total number of shares will commence on Monday, 18 August 2025, on the official list of Nasdaq Helsinki Ltd under the new ISIN code FI4000591698. The Company's trading code DIGIGR will remain unchanged. The Extraordinary General Meeting of the Company held on 13 August 2025 resolved on the combination of shares and the related redemption of shares so that after the combination of shares, one (1) share in the Company corresponds to every 250 shares in the Company. In connection with the implementation of the combination of shares, the Board of Directors resolved to implement the directed share issue without consideration resolved by the Extraordinary General Meeting, in which the Company has transferred without consideration in total 636,238 of its own shares held by the Company, so that the number of shares recorded in each book-entry account holding shares in the Company is divisible by 250. The total market value of the shares transferred without consideration, based on the closing price on 15 August 2025, was approximately 11,706.78 euros. Following the directed share issue, the Company has redeemed without consideration 249 shares for each 250 shares in the Company, in accordance with the resolution of the Extraordinary General Meeting. The shares of the Company redeemed in connection with the combination of shares have been cancelled immediately. In addition, in connection with the combination of shares, a total of 205 of the Company's own shares held by the Company were cancelled in order for the number of the Company's own shares held by the Company and the total number of shares in the Company to be divisible by 250. Following the combination of shares, Digitalist Group holds 28,114 of its own shares. The purpose of the combination of shares is to improve the prerequisites for trading in the Company's shares by increasing the value of an individual share and to enhance the formation of the share price. The procedure relating to the combination of shares is described in more detail in the stock exchange release published by Digitalist Group on 13 August 2025 concerning the resolutions of the Extraordinary General Meeting. In accordance with the provisions of the Finnish Limited Liability Companies Act regarding related party transactions, the members of the Board of Directors of Digitalist Group, Paul Ehrnrooth and Peter Eriksson, did not participate in the decision-making concerning Turret Oy Ab in relation to the combination of shares. Adjustment of the maximum numbers of shares in the Company available for subscription under the Company's convertible loan instruments and the 2021 stock option programme, as well as the subscription prices As a consequence of the implementation of the combination of the Company's shares, the Board of Directors of the Company resolved on the changes resulting from the combination of shares as set out below: to the maximum numbers of new shares in the Company available for subscription, and to the subscription prices, under the Company's convertible loan instruments subscribed for by Turret Oy Ab ('Turret') and Holdix Oy Ab ('Holdix') (each a 'Convertible Loan' and together the 'Convertible Loans') 2021/1, 2021/2, 2021/3, 2021/4, 2022/1, 2025/1 and 2025/2, in accordance with the terms and conditions (the 'Terms and Conditions') of the respective instruments; and to the maximum numbers of new shares in the Company available for subscription, and to the subscription prices, under the option rights granted pursuant to the Company's 2021 Stock Option Program, and partly to the lapse of certain option rights. Convertible Loans 2021/1, 2021/3, 2022/1 and 2025/1 The Board of Directors of the Company resolved on the following changes to the maximum numbers of new shares in the Company available for subscription, and to the subscription prices, under the Convertible Loans 2021/1, 2021/3, 2022/1 and 2025/1 subscribed for by Turret: In accordance with Clause 11 of the terms and conditions of the Convertible Loans (the 'Terms and Conditions'), the Conversion Price of a share (meaning the per-share subscription price under the Finnish Limited Liability Companies Act) shall be the volume-weighted average price of the Company's share on Nasdaq Helsinki Ltd during the six (6) months preceding the delivery of a Conversion Notice as defined in Clause 13 of the Terms and Conditions, provided, however, that the volume-weighted average price of the Company's share calculated for the period preceding 18 August 2025 shall be multiplied by 250; The bonds under Convertible Loan 2021/1 may be converted into a maximum of 260,000 new shares in the Company; The bonds under Convertible Loan 2021/3 may be converted into a maximum of 5,204,280 new shares in the Company; The bonds under Convertible Loan 2022/1 may be converted into a maximum of 772,600 new shares in the Company; The bonds under Convertible Loan 2025/1 may be converted into a maximum of 951,772 new shares in the Company. In accordance with the provisions of the Finnish Limited Liability Companies Act regarding related party transactions, the members of the Board of Directors of Digitalist Group, Paul Ehrnrooth and Peter Eriksson, did not participate in the decision-making concerning Convertible Loans 2021/1, 2021/3, 2022/1 and 2025/ Loans 2021/2, 2021/4 and 2025/2 The Board of Directors of the Company resolved on the following changes to the maximum numbers of new shares in the Company available for subscription, and to the subscription prices, under the Convertible Loans 2021/2, 2021/4 and 2025/2 subscribed for by Holdix: In accordance with Clause 11 of the terms and conditions of the Convertible Loans (the 'Terms and Conditions'), the Conversion Price of a share (meaning the per-share subscription price under the Finnish Limited Liability Companies Act) shall be the volume-weighted average price of the Company's share on Nasdaq Helsinki Ltd during the six (6) months preceding the delivery of a Conversion Notice as defined in Clause 13 of the Terms and Conditions, provided, however, that the volume-weighted average price of the Company's share calculated for the period preceding 18 August 2025 shall be multiplied by 250; The bonds under Convertible Loan 2021/2 may be converted into a maximum of 140,000 new shares in the Company; The bonds under Convertible Loan 2021/4 may be converted into a maximum of 2,424,450 new shares in the Company; The bonds under Convertible Loan 2025/2 may be converted into a maximum of 377,584 new shares in the Option Program 2021 Digitalist Group has only one stock option program in force, namely the Stock Option Program 2021. All valid option rights granted to recipients under the Stock Option Program 2021 have been designated with the identifier 2021A2 ('Option Rights 2021A2'), and no other option rights with different identifiers under the Stock Option Program 2021 remain in force. Each Option Right 2021A2 entitles its holder to subscribe for one new share in the Company. Before the combination of shares, there were 7,300,000 Option Rights 2021A2 in force, and under their terms the subscription price for new shares in the Company with the Option Rights 2021A2 was EUR 0.0298 per share. The subscription period for the Option Rights 2021A2 commences on 1 January 2026 and ends on 31 December 2026. On 15 August 2025, the Board of Directors of the Company resolved to amend the terms of the Option Rights 2021A2 granted under the Stock Option Program 2021 so as to take into account the combination of shares as follows: the Option Rights 2021A2 may be used to subscribe for a maximum of 29,200 new shares in the Company; and the subscription price for the new shares in the Company to be subscribed for with the Option Rights 2021A2 shall be EUR 7.45 per share. The Board of Directors of the Company resolved that the other option rights under the Stock Option Program 2021 (2021A1, 2021B1, 2021B2 and 2021C1) have lapsed. DIGITALIST GROUP PLC Board of Directors For further information, please contact: CEO Magnus Leijonborg, tel. +46 76 315 8422, Chair of the Board: Esa Matikainen, tel. +358 40 506 0080, Distribution: Nasdaq Helsinki Ltd Main media Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
